Expert Review of Vaccines

Papers
(The TQCC of Expert Review of Vaccines is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Estimating the lifetime cost of vaccination in 23 European Countries: a modeling study182
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic166
Safety profile of COVID-19 vaccines, preventive strategies, and patient management137
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy89
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant 85
Toward an effective Staphylococcus vaccine: why have candidates failed and what is the next step?83
Additional considerations for anti-tick vaccine research72
Evaluating the reactogenicity of COVID-19 vaccines from network-meta analyses71
Immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population66
Challenges in vaccine transport: can we deliver without the cold chain?65
Response to: letter to “Self-controlled case series design in vaccine safety: a systematic review”63
Safety of primary immunization with a DTwP-HBV/Hib vaccine in healthy infants: a prospective, open-label, interventional, phase IV clinical study59
Further implications on the global real-world vaccine effectiveness against SARS-CoV-258
Overcoming scientific barriers in the transition fromin vivoto non-animal batch testing of human and veterinary vaccines56
Relationship between attitudes toward the effectiveness of vaccine, concerns about adverse reactions, and proactively taking SARS-Cov-2 vaccine for family among medical workers in Taizhou, China56
COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study56
Pneumococcal vaccine implementation in the African meningitis belt countries: the emerging need for alternative strategies55
A review of data systems for assessing the impact of HPV vaccination in selected high-income countries50
Eradicating polio in Pakistan: a systematic review of programs and policies50
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?49
Estimating the time required to reach HPV vaccination targets across Europe49
Indirect protection from rotavirus vaccines: a systematic review48
Global prevalence of acceptance of COVID-19 vaccines and associated factors in pregnant women: a systematic review and meta-analysis44
Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma: a systematic literature review and narrative synthesis43
Parental category B vaccine hesitancy and associated factors in China: an online cross-sectional survey41
The associations of geographic location and perceived risk of infection with the intentions to get vaccinated against COVID-19 in China41
Approaches in broadening the neutralizing antibody response of the influenza vaccine40
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States38
COVID-19 vaccine equity: a health systems and policy perspective36
Measuring psychosocial determinants of vaccination behavior in healthcare professionals: validation of the Pro-VC-Be short-form questionnaire36
Should we be vaccinating children against COVID-19 in high-income countries?35
Current status of COVID-19 vaccination: safety and liability concern for children, pregnant and lactating women34
Public preferences and willingness to accept a hypothetical vaccine to prevent a pandemic in Japan: a conjoint analysis33
The influence of selected factors on the immunogenicity of preventive vaccinations against hepatitis A, B and influenza in solid organ transplant recipients undergoing immunosuppressive therapy – a re32
The iNTS-GMMA vaccine: a promising step in non-typhoidal Salmonella vaccine development32
Influenza vaccine: progress in a vaccine that elicits a broad immune response32
Monkeypox: a new face of outbreak32
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks32
Vaccination deferral among children with seizures in Zhejiang: influence, recommendation, safety and implications31
Synergistic activity of antibodies in the multicomponent 4CMenB vaccine29
Understanding immunity to influenza: implications for future vaccine development29
Controlled human infection models to evaluate schistosomiasis and hookworm vaccines: where are we now?28
Immunization in state of siege: the importance of thermostable vaccines for Ukraine and other war-torn countries and territories28
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: a scoping review28
No association between enterovirus 71 (EV71) vaccination and risk of febrile seizures: a population-based near real-time surveillance study27
Immunogenicity and safety of a high-dose and prolonged-schedule hepatitis B vaccine among chronic kidney disease patients: a randomized, parallel-controlled trial27
The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines26
Immune to addiction: how immunotherapies can be used to combat methamphetamine addiction25
Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial25
To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination25
A scoping review of literature exploring factors affecting vaccine uptake within Roma communities across Europe24
Recommendations to drive a value-based decision-making on vaccination24
Cost-effectiveness of nonavalent HPV vaccination in the Netherlands24
Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity24
Correction23
The mRNA vaccine, a swift warhead against a moving infectious disease target23
Impact of rotavirus vaccination on diarrheal disease burden of children in South America22
Adult vaccination against respiratory infections in Egypt: a review of expert opinions22
Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US22
Tackling vaccine inequity in 2023: have we made progress?22
Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells21
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response21
Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States21
Nonhuman primate models for evaluation of SARS-CoV-2 vaccines20
Chlamydia trachomatisvaccine development – a view on the current challenges and how to move forward20
PreHevbrio: the first approved 3-antigen hepatitis B vaccine20
Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis20
Invasive meningococcal disease epidemiology and vaccination strategies in four Southern European countries: a review of the available data20
Respiratory syncytial virus infection and the need for immunization in Korea20
PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children20
Real-world impact of rotavirus vaccination in European healthcare settings: a systematic literature review19
Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine19
Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies18
Influenza B virus neuraminidase: a potential target for next-generation vaccines?18
Effectiveness of pneumococcal vaccination on hospitalization and death in the adult and older adult diabetic population: a systematic review18
Overcoming roadblocks in the development of vaccines for leishmaniasis18
Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine17
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review17
Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations17
HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine17
Evolution of A(H1N1) pdm09 influenza virus masking by glycosylation17
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children17
Current development of Zika virus vaccines with special emphasis on virus-like particle technology17
Efficacy, immunogenicity, and evidence for best-timing of pneumococcal vaccination in splenectomized adults: a systematic review17
Reduced mother-to-child transmission of hepatitis B after implementation of completely charge-free active-passive immunoprophylaxis: an observational cohort study16
A policy review of the introduction of the MenACWY vaccine in toddlers across multiple countries16
No observable influence of COVID-19 inactivated vaccines on pregnancy and birth outcomes in the first trimester of gestation16
Public health impact and return on investment of the pediatric immunization program in Poland16
SARS-CoV-2 the ASIA virus (Autoimmune/autoinflammatory Syndrome Induced by Adjuvants), the risk of infertility and vaccine hesitancy16
A journey worth taking: global eradication of measles, rubella and congenital rubella syndrome16
Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumo16
Development of a recombinant vaccine against human onchocerciasis16
Immunogenicity and safety of seasonal influenza vaccines in children under 3 years of age15
Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance15
Progress Towards a Therapeutic HIV DNA Vaccine15
Changes in vaccine administration trends across the life-course during the COVID-19 pandemic in the United States: a claims database study15
Modern vaccine strategies for emerging zoonotic viruses15
Have mRNA vaccines sentenced DNA vaccines to death?15
Shoulder injury following COVID-19 vaccine administration: a case series and proposed diagnostic algorithm15
COVID-19 vaccines: concerns beyond protective efficacy and safety15
Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-1915
Controlling the COVID-19 pandemic through vaccination: a perspective from Indonesia14
Immunomodulatory regulation by heat-labile enterotoxins and potential therapeutic applications14
The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?14
Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses14
Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness14
Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants14
Vaccination strategies between compulsion and incentives. The Italian Green Pass experience14
Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-214
Construction of a multiepitope vaccine candidate against Fasciola hepatica : an in silico design using various immunogenic excretory/secre14
Expert review on global real-world vaccine effectiveness against SARS-CoV-214
The road to achieving herd immunity: factors associated with Singapore residents’ uptake and hesitancy of the COVID-19 vaccination13
Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices13
COVID-19 vaccine coverage, concerns, and preferences among Chinese ICU clinicians: a nationwide online survey13
Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study13
Public health impact and return on investment of the pediatric National Immunization Program in Italy13
Translating meningococcal serogroup B vaccines for healthcare professionals13
Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment13
Eyedrop vaccination: an immunization route with promises for effective responses to pandemics13
Developing variant-adapted COVID-19 vaccines to improve protection against Omicron and other recent variants: a plain language summary13
Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs13
The potential utility of liposomes forNeisseriavaccines13
COVID-19 vaccination hesitancy in Italian healthcare workers: a systematic review and meta-analysis13
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom13
Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs13
Global impact of delta plus variant and vaccination12
Nano-vaccines for gene delivery against HIV-1 infection12
Challenges targeting cancer neoantigens in 2021: a systematic literature review12
Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study12
Vaccine development for pathogenic fungi: current status and future directions12
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: inte12
Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom12
Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?12
0.051831007003784